TELIK –

South San Francisco, Calif.

Went public 8/11/2000 at $7 per share

Filing Range: 5 mil. shares @ $9 to $11

Shares Outstanding: 21.6 mil. shares

Underwriters: Lehman Brothers/Chase H&Q/Legg Mason Wood Walker/UBS

Warburg/ Fidelity Capital Markets

Company Counsel: Cooley Godward LLP

Manager Counsel: Sullivan & Cromwell

Auditor: Ernst & Young LLP

The Company:

Designs molecular drugs for the pharmaceutical industry. This biotechnology company’s core technology is designated PIN (pseudo-idiotypic network) and encompasses a molecular indexing technique by which molecular shapes can be sorted and catalogued. With this information, the company hopes to identify novel compounds that attach to therapeutic agents.

Venture Backers:

Weiss, Peck & Greer Venture Partners LP

Delphi Ventures

Advent International Corp.

Sofinnova Ventures

Alta Partners

Alpha Capital Venture Partners LP

Burr, Egan, Deleage & Co.

Oxford Bioscience Partners

Technology Funding

Hambrecht & Quist

S.R. One Ltd.

MDS Health Ventures Inc.

New Enterprise Associates

Financing Rounds:

Number of Round Amt.

Round # Round Date Stage Investors ($ thousands)

1 08/01/1992 3 Early Stage 3800.0

2 12/03/1992 7 Early Stage 13187.2

3 08/26/1994 10 Later Stage 4999.8

4 10/01/1994 3 Later Stage 4000.0

5 4/01/1995 2 Later Stage 125.0

6 07/01/1995 2 Later Stage 125.0

7 11/22/1995 13 Later Stage 3362.0

8 01/01/1996 2 Later Stage 125.0

9 07/01/1996 4 Buyout/Acquisition 134.0

10 09/23/1997 1 Later Stage 691.0

11 11/13/1997 10 Later Stage 6459.0

12 10/01/1998 2 Later Stage 10500.0

13 03/31/2000 2 Later Stage 7000.0

Financials:

(Data in $ millions)

Y/E

12/31/99

Total Revenues: $4.2

Net Income: -7.1